Generics Behaving Badly: Carve Outs, Off-Label Uses
However, with an estimated $65 billion of drugs coming off patent protection in the next five years, generics stand ready to cash in on this bonanza. As the competitive landscape undergoes enormous changes, pioneers need to coordinate their IP and regulatory strategies to protect new investments in old drugs.
Hatch-Waxman: Then and Now
For the past...
To view the full article, register now.